Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Working Capital Changes (2021 - 2025)

Historic Other Working Capital Changes for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to -$1.1 million.

  • ARS Pharmaceuticals' Other Working Capital Changes fell 31210.32% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 74896.23%. This contributed to the annual value of $6.2 million for FY2024, which is 29735.42% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Other Working Capital Changes is -$1.1 million, which was down 31210.32% from -$4.1 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $7.3 million during Q4 2024, with a 5-year trough of -$4.1 million in Q2 2025.
  • In the last 5 years, ARS Pharmaceuticals' Other Working Capital Changes had a median value of -$486500.0 in 2021 and averaged -$71312.5.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first plummeted by 687000.0% in 2024, then skyrocketed by 65317.19% in 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Other Working Capital Changes (Quarter) stood at -$1.7 million in 2021, then soared by 89.02% to -$189000.0 in 2022, then skyrocketed by 94.71% to -$10000.0 in 2023, then soared by 72610.0% to $7.3 million in 2024, then plummeted by 114.74% to -$1.1 million in 2025.
  • Its Other Working Capital Changes stands at -$1.1 million for Q3 2025, versus -$4.1 million for Q2 2025 and $4.8 million for Q1 2025.